Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Tadalafil and magnesium?

See the DrugPatentWatch profile for Tadalafil

Tadalafil is a medication used to treat erectile dysfunction and symptoms of benign prostatic hyperplasia. It belongs to a class of drugs called phosphodiesterase type 5 (PDE5) inhibitors. The specific interaction between tadalafil and magnesium is not extensively detailed in readily available public information, but magnesium plays a role in many bodily functions, including muscle and nerve function.

Can you take magnesium with tadalafil?


Information on the direct interaction of taking magnesium supplements with tadalafil is limited. However, as magnesium is an essential mineral involved in numerous physiological processes, it is generally considered safe for most individuals. Patients should consult their healthcare provider or pharmacist for personalized advice regarding the use of magnesium supplements alongside tadalafil, especially if they have any pre-existing health conditions or are taking other medications.

What other drugs interact with tadalafil?


Tadalafil can interact with several types of medications. Notably, it should not be taken with nitrate medications used for chest pain, as this combination can cause a dangerous drop in blood pressure. Other significant interactions include alpha-blockers, used to treat high blood pressure or an enlarged prostate, and certain antifungal or antibacterial medications that can increase tadalafil levels in the blood. Patients should always provide a comprehensive list of all medications, including over-the-counter drugs and supplements, to their doctor before starting tadalafil [1].

How does tadalafil work?


Tadalafil works by increasing blood flow to the penis during sexual stimulation. It achieves this by blocking the action of an enzyme called PDE5. This enzyme is responsible for breaking down a substance called cyclic guanosine monophosphate (cGMP). By inhibiting PDE5, tadalafil allows cGMP to accumulate, leading to relaxation of the smooth muscles in the blood vessels of the penis. This relaxation permits more blood to flow into the penis, resulting in an erection [2].

What are the side effects of tadalafil?


Common side effects of tadalafil can include headache, indigestion, back pain, muscle aches, flushing, and nasal congestion. These side effects are typically mild and temporary. Less common but more serious side effects can occur, such as sudden vision or hearing loss, or an erection that lasts longer than four hours (priapism), which requires immediate medical attention. Individuals experiencing any concerning side effects should seek medical advice [1].

How long does tadalafil stay in your system?


Tadalafil has a relatively long half-life, meaning it remains in the body for an extended period. Its half-life is approximately 17.5 hours. This allows for a window of effectiveness of up to 36 hours after taking a single dose, which is why it is sometimes referred to as the "weekend pill" [2].

When does tadalafil patent expire?


The original patents for tadalafil have expired in many regions, leading to the availability of generic versions. For instance, in the United States, the primary patents for Cialis (tadalafil) expired, allowing for generic entry. DrugPatentWatch.com tracks patent expiry dates for pharmaceuticals globally, providing detailed information on patent status for various medications, including tadalafil [3].

What are the alternatives to tadalafil?


Alternatives to tadalafil for treating erectile dysfunction include other PDE5 inhibitors such as sildenafil (Viagra), vardenafil (Levitra), and avanafil (Stendra). Other treatment options may involve vacuum erection devices, penile injections, urethral suppositories, or surgical implants. For benign prostatic hyperplasia, other medications and treatment approaches are available. A healthcare provider can recommend the most suitable alternative based on individual health status and needs.

---
1. Tadalafil. (n.d.). National Library of Medicine. Retrieved from https://medlineplus.gov/druginfo/meds/a604013.html
2. Cialis. (n.d.). RxList. Retrieved from https://www.rxlist.com/cialis-drug.htm
3. DrugPatentWatch.com. (n.d.). Retrieved from https://drugpatentwatch.com/



Other Questions About Tadalafil :

Can tadalafil treat enlarged prostate symptoms? Tadalafil and ibuprofen? Tadalafil oral liquid? Tadalafil 20 mg price in egypt? Tadalafil in thailand? Teva tadalafil approval status in japan? Tadalafil compound?

AI-Drug Label Prescribing Information Alignment Report

Patient Risk: Low

Summary

The AI-generated claims largely align with the FDA label for tadalafil (ED/BPH indication, PDE5 mechanism, key interactions with nitrates, alpha-blockers, and CYP3A modulators, common and serious adverse effects, pharmacokinetics). Some magnesium-specific interaction details and broader non-label alternatives/patents/generic status are not present in the label and are treated as omissions or unsupported claims.


Category Scores

Indication
100
Excellent
Indication
100
Excellent
Indication
100
Excellent
Indication
100
Excellent
Indication
100
Excellent

Accurate Statements

Tadalafil is marketed for erectile dysfunction and for symptoms of benign prostatic hyperplasia.
Section 17 (PATIENT COUNSELING INFORMATION) indicates tadalafil is marketed as Cialis for ED and BPH symptoms.
Tadalafil is a phosphodiesterase type 5 (PDE5) inhibitor.
Section 12.1 (Mechanism of Action) describes tadalafil as a PDE5 inhibitor.
Tadalafil works by increasing blood flow to the penis during sexual stimulation by inhibiting PDE5, which degrades cGMP.
Section 12.1 (Mechanism) describes PDE5 inhibition leading to increased cGMP and vascular effects.
Inhibiting PDE5 allows cGMP to accumulate, leading to relaxation of smooth muscles in penile blood vessels and increased penile blood flow.
Section 12.1 (Mechanism) describes accumulation of cGMP and downstream relaxation.
Common side effects include headache, indigestion, back pain, muscle aches, flushing, and nasal congestion, typically mild and temporary.
Section 6 (Adverse Reactions) lists these as common adverse effects and characterizes them as typically mild/temporary.
Less common but serious adverse effects include sudden vision loss and sudden hearing loss.
Section 5.3 (Visual Loss) and Section 5.4 (Hearing Impairment) describe these events.
An erection lasting longer than four hours (priapism) can occur and requires emergency medical attention.
Section 5.6 (Prolonged Erection) describes priapism and urgent attention.
Tadalafil has a half-life of approximately 17.5 hours, with a window of effectiveness up to about 36 hours after a dose.
Section 12.3 (Pharmacokinetics) provides the half-life and extended window.
Tadalafil should not be used with organic nitrates; coadministration can cause dangerous hypotension.
Section 4.1 (Concomitant Nitrates) states contraindication with nitrates.
Alpha-blockers and PDE5 inhibitors can have additive vasodilatory effects; interactions with doxazosin, alfuzosin, or tamsulosin are noted.
Section 7.2 (Alpha-Blockers) describes additive BP-lowering effects.
CYP3A inhibitors/inducers can increase tadalafil levels in the blood.
Section 7.5 (CYP3A Inhibitors/Inducers) discusses interactions with modulators of CYP3A.
Tadalafil is marketed as Cialis for ED and for BPH, as referenced in patient labeling.
Section 17 (PATIENT COUNSELING INFORMATION) notes the Cialis branding for ED and BPH.
The mechanism describes increasing penile blood flow via PDE5 inhibition and cGMP accumulation leading to erection.
Section 12.1 (Mechanism) details this pharmacodynamic sequence.
Common adverse effects include headache, indigestion, back pain, muscle aches, flushing, and nasal congestion.
Section 6 (Adverse Reactions) lists these specific effects.
These side effects are typically mild and temporary.
Section 6 (Adverse Reactions) describes them as generally mild/temporary.

Unsupported Statements

Magnesium plays a role in many bodily functions, including muscle and nerve function.
Label does not discuss magnesium or its physiological roles.
The specific interaction between tadalafil and magnesium is not extensively detailed in readily available public information.
Label does not discuss magnesium interactions.
Information on the direct interaction of taking magnesium supplements with tadalafil is limited.
Label does not provide magnesium-specific interaction details.
Magnesium is an essential mineral involved in numerous physiological processes.
Label does not discuss magnesium.
It is generally considered safe for most individuals.
Label does not provide a general safety statement about magnesium.
Patients should always provide a comprehensive list of all medications, including over-the-counter drugs and supplements, to their doctor before starting tadalafil.
Label/Counseling cautions exist but do not explicitly require a comprehensive meds list.
Alternatives to tadalafil for treating erectile dysfunction include other PDE5 inhibitors such as sildenafil, vardenafil, and avanafil.
Label does not discuss alternative PDE5 inhibitors.
Other treatment options may involve vacuum erection devices, penile injections, urethral suppositories, or surgical implants.
Label does not enumerate non-pharmacologic ED treatments.
For benign prostatic hyperplasia, other medications and treatment approaches are available.
Label does not enumerate BPH alternatives.
A healthcare provider can recommend the most suitable alternative based on individual health status and needs.
Label does not provide explicit guidance on selecting alternatives.

Contradictions


Important Omissions

Explicit dosing or administration instructions for tadalafil are not provided in the claims.
Importance: High
Storage and handling details for tadalafil are not covered by the claims.
Importance: Moderate
Use in specific populations (e.g., pregnancy, pediatric use) details are not covered by the claims.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Low
Claims align with label's major safety warnings (nitrate contraindication, alpha-blocker and CYP3A interactions, common/serious adverse effects, priapism) with no emergent new safety concerns introduced by the claims.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue

Suggested Improvement
Include explicit dosing/administration details if evaluating dosage claims, and consider adding a caveat about non-pharmacologic ED treatments and patent/generic status if relevant to the user's use case.